Anti-cancer Therapy with TNFα and IFNγ: A Comprehensive Review

Overview

Journal Cell Prolif

Date 2018 Feb 28

PMID 29484738

Citations 59

Authors

Jing Shen

Zhangang Xiao

Qijie Zhao

Mingxing Li

Xu Wu

Lin Zhang

Wei Hu

Chi H Cho

Affiliations

Soon will be listed here.

Abstract

Tumour necrosis factor alpha (TNFα) and interferon gamma (IFNγ) were originally found to be produced by inflammatory cells and play important roles in the immune system and surveillance of tumour growth. By activating distinct signalling pathways of nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), and JAK/STAT, TNFα and IFNγ were reported to effectively trigger cell death and perform powerful anti-cancer effects. In this review, we will discuss the new advancements of TNFα and IFNγ in anti-cancer therapy.

Citing Articles

Targeted approach to determine the impact of cancer-associated protease variants.

Bickenbach K, David N, Koudelka T, Joos C, Scharfenberg F, Ruffer M Sci Adv. 2025; 11(7):eadp5958.

PMID: 39937919 PMC: 11818018. DOI: 10.1126/sciadv.adp5958.

Effects of FAP+ fibroblasts on cell proliferation migration and immunoregulation of esophageal squamous carcinoma cells through the CXCL12/CXCR4 axis.

Duan L, Cao S, Zhao F, Du X, Gao Z, Wang X Mol Cell Biochem. 2025; .

PMID: 39934460 DOI: 10.1007/s11010-025-05226-x.

Genomic profiling of intimal sarcoma reveals molecular subtypes with distinct tumor microenvironments and therapeutic implications.

Park C, Kim R, Bae J, Lee T, Song S, Kwak Y ESMO Open. 2025; 10(1):104097.

PMID: 39778225 PMC: 11758979. DOI: 10.1016/j.esmoop.2024.104097.

Trigger inducible tertiary lymphoid structure formation using covalent organic frameworks for cancer immunotherapy.

Zhang L, Zhang B, Zhang M, Li W, Li H, Jiao Y Nat Commun. 2025; 16(1):44.

PMID: 39747845 PMC: 11696883. DOI: 10.1038/s41467-024-55430-4.

The functional TNF-αG > a single-nucleotide polymorphism (rs1800629): association with the predictive indices of breast cancer carcinogenesis.

Refaat S, Al-Rashidi H, El Azeem R, Nouh W, Hamed S, Attia Z Breast Cancer Res Treat. 2024; 210(1):57-70.

PMID: 39570546 PMC: 11787156. DOI: 10.1007/s10549-024-07536-y.

References

Kim W, Lee J, Gao B, Jung M . Synergistic activation of JNK/SAPK induced by TNF-alpha and IFN-gamma: apoptosis of pancreatic beta-cells via the p53 and ROS pathway. Cell Signal. 2005; 17(12):1516-32. DOI: 10.1016/j.cellsig.2005.03.020. View

Alexander Jr H, Bartlett D, Libutti S, Fraker D, Moser T, Rosenberg S . Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998; 16(4):1479-89. DOI: 10.1200/JCO.1998.16.4.1479. View

Fraker D, Alexander H, Andrich M, Rosenberg S . Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol. 1996; 14(2):479-89. DOI: 10.1200/JCO.1996.14.2.479. View

Lejeune F, Lienard D, Matter M, Ruegg C . Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 2006; 6:6. View

Quesada J, Kurzrock R, Sherwin S, Gutterman J . Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J Biol Response Mod. 1987; 6(1):20-7. View

Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A . Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol. 2000; 18(11):1185-90. DOI: 10.1038/81183. View

Qin Z, Blankenstein T . CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity. 2000; 12(6):677-86. DOI: 10.1016/s1074-7613(00)80218-6. View

Schiller J, Pugh M, Kirkwood J, Karp D, Larson M, Borden E . Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res. 1996; 2(1):29-36. View

Jett J, Maksymiuk A, Su J, Mailliard J, Krook J, Tschetter L . Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol. 1994; 12(11):2321-6. DOI: 10.1200/JCO.1994.12.11.2321. View

10.

Lane H, Davey Jr R, Sherwin S, Masur H, Rook A, Manischewitz J . A phase I trial of recombinant human interferon-gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS). J Clin Immunol. 1989; 9(4):351-61. DOI: 10.1007/BF00918667. View

11.

Kulkarni K, Selesniemi K, Brown T . Interferon-gamma sensitizes the human salivary gland cell line, HSG, to tumor necrosis factor-alpha induced activation of dual apoptotic pathways. Apoptosis. 2006; 11(12):2205-15. DOI: 10.1007/s10495-006-0281-8. View

12.

Gasparri A, Moro M, Curnis F, Sacchi A, Pagano S, Veglia F . Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models. Cancer Res. 1999; 59(12):2917-23. View

13.

Kimura M, Haisa M, Uetsuka H, Takaoka M, Ohkawa T, Kawashima R . TNF combined with IFN-alpha accelerates NF-kappaB-mediated apoptosis through enhancement of Fas expression in colon cancer cells. Cell Death Differ. 2003; 10(6):718-28. DOI: 10.1038/sj.cdd.4401219. View

14.

CARSWELL E, Old L, Kassel R, Green S, Fiore N, Williamson B . An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975; 72(9):3666-70. PMC: 433057. DOI: 10.1073/pnas.72.9.3666. View

15.

Zhang G . Tumor necrosis factor family ligand-receptor binding. Curr Opin Struct Biol. 2004; 14(2):154-60. DOI: 10.1016/j.sbi.2004.03.003. View

16.

Johansson A, Hamzah J, Payne C, Ganss R . Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci U S A. 2012; 109(20):7841-6. PMC: 3356673. DOI: 10.1073/pnas.1118296109. View

17.

Cai W, Kerner Z, Hong H, Sun J . Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha. Biochem Insights. 2013; 2008:15-21. PMC: 3792586. View

18.

Joyce J, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D . Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 2003; 4(5):393-403. DOI: 10.1016/s1535-6108(03)00271-x. View

19.

Pujade-Lauraine E, Guastalla J, Colombo N, Devillier P, Francois E, Fumoleau P . Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol. 1996; 14(2):343-50. DOI: 10.1200/JCO.1996.14.2.343. View

20.

Pankov R, Yamada K . Fibronectin at a glance. J Cell Sci. 2002; 115(Pt 20):3861-3. DOI: 10.1242/jcs.00059. View